IG
CBAY

ING Group’s Cymabay Therapeutics CBAY Stock Holding History

ING Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-145,000
Closed -$1.04M – 784
2019
Q2 		$1.04M Buy
145,000
+57,068
+65% +$646K 0.02% 373
2019
Q1 		$1.17M Sell
87,932
-29,500
-25% -$314K 0.03% 293
2018
Q4 		$924K Buy
+117,432
New +$1.12M 0.02% 346

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

ING Group's CBAY Position: Q3 2019 in Review

ING Group sold out of Cymabay Therapeutics (CBAY) in Q3 2019, closing a stake of 145,000 shares — an estimated $1.04M sold.

ING Group first reported a position in CBAY in Q4 2018 and held it in 3 quarters. The position peaked at $1.17M in Q1 2019. 137 funds tracked by Wall St. Rank hold CBAY as of Q3 2019.

  • ING Group reported no remaining Cymabay Therapeutics position as of Q3 2019 after selling out during the quarter.
  • ING Group sold 145,000 Cymabay Therapeutics shares in Q3 2019, an estimated $1.04M.
  • ING Group first reported a position in Cymabay Therapeutics in Q4 2018 and held it in 3 quarters.
  • ING Group's Cymabay Therapeutics position peaked at $1.17M in Q1 2019.
  • 137 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2019.

Based on ING Group's 13F filing for Q3 2019, filed 8 Nov 2019.